YZYBIO-B(02496.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
YZYBIO-B
02496.HK
Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related ophthalmologic diseases. The company develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma, and other advanced solid tumors; wAMD, DME, and other ocular neovascularization-related diseases; hemophilia; and inflammatory bowel diseases. Wuhan YZY Biopharma Co., Ltd. was founded in 2010 and is headquartered in Wuhan, China.
1.304 T
02496.HKMarket value -Rank by Market Cap -/-

Financial Score

28/01/2026 Update
C
BiotechnologyIndustry
Industry Ranking36/53
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-704.81%E
    • Profit Margin-52.25%E
    • Gross Margin33.47%C
  • Growth ScoreB
    • Revenue YoY3934.19%A
    • Net Profit YoY57.42%B
    • Total Assets YoY-6.11%D
    • Net Assets YoY-156.37%E
  • Cash ScoreB
    • Cash Flow Margin-191.38%D
    • OCF YoY3934.19%A
  • Operating ScoreB
    • Turnover0.6B
  • Debt ScoreE
    • Gearing Ratio111.45%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Wuhan YZY Biopharma Submits CSRC Filing for H Share Full Circulation

    Wuhan YZY Biopharma Co., Ltd. has submitted a filing to the China Securities Regulatory Commission (CSRC) for the proposed implementation of H share full circulation, converting 68,010,299 domestic shares into H shares. The process is pending further approvals from the CSRC, Hong Kong Stock Exchange, and other regulatory authorities. Updates will be provided as necessary.

    Reuters·
    HK
    02496
    +2.32%
    Reuters·
    HK
    02496
    +2.32%

    Wuhan Yzy Biopharma Sells Land Use Right and Building to Wuhan Yiruide

    Wuhan Yzy Biopharma Co. Ltd. has announced a transaction involving the sale of land use rights and buildings to Wuhan Yiruide Medical Treatment Equipment New Technology Co., Ltd. The agreement, signed on January 23, 2026, covers approximately 11,333.22 square meters of gross floor area and is classified as a discloseable transaction under Hong Kong Stock Exchange Listing Rules.

    Reuters·
    HK
    02496
    +2.32%
    Reuters·
    HK
    02496
    +2.32%

    YZYBIO is selling industrial land in Wuhan for RMB 36.88 million

    YZYBIO-B announced the transfer of an unused industrial building located in the east of Wuhan City, Hubei Province, with a land area of approximately 25,533 square meters, to Wuhan Yiruid. The cash consideration is RMB 36.88 million

    AASTOCKS·
    HK
    02496
    +2.32%
    AASTOCKS·
    HK
    02496
    +2.32%

    YZYBIO's biosimilar Y225 clinical trial application approved

    YZYBIO-B announced that the clinical trial application for the biosimilar drug Y225 has been approved by the National Medical Products Administration of China. Y225 is a bispecific antibody biosimilar used for the treatment of Hemophilia A, specifically the drug Shuyou Lile (Aimeisai Zhu Dan Zhi Ye, anti-FIX and FX)

    AASTOCKS·
    HK
    02496
    +2.32%
    AASTOCKS·
    HK
    02496
    +2.32%

    YZYBIO-B: Mid-term data from the Phase II study of M701 for malignant pleural effusion will be announced at the 2025 ESMO conference

    YZYBIO-B announced that the mid-term data of its bispecific antibody M701 in the Phase II clinical study for the treatment of malignant pleural effusion caused by advanced non-small cell lung cancer has been presented at the 2025 European Society for Medical Oncology (ESMO). The study is a randomized, controlled, multicenter, open-label trial, with the primary endpoint being puncture-free survival time, and secondary endpoints including the objective response rate of malignant pleural effusion. As of March 7, 2025, a total of 54 patients participated, with 26 in the experimental group and 28 in the control group

    Zhitong·
    HK
    02496
    +2.32%
    Zhitong·
    HK
    02496
    +2.32%
    © 2026 Longbridge｜Disclaimer